Idec Stock Recovers Slightly After Analyst's Downgrade
Biotech: Lymphoma Drug's Near-Term Growth Potential Is Uncertain

Senior Staff Writer

Shares of Idec Pharmaceuticals Corp...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129